Exabis Library
Welcome to the e-CCO Library!
P690: Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P690: Rates of IBD in New Zealand Māori population at Lakes District Health Board: low but increasing
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P691: Disparate care: rates of treat to target among patients with inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P691: Influence of ethnicity on the phenotype and clinical outcomes in Inflammatory Bowel Disease; comparison of a South American with a North American population.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P691: UV exposure and skin type are more important than thiopurine exposure for non-melanoma skin cancer risk in IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P692: Clinical, therapeutic and evolutionary profile of fistulizing ano-perineal lesions in Crohn's disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic review
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P692: Inflammatory bowel diseases in Faroese-born Danish residents and their offspring. Further evidence of the dominant role of environmental factors in IBD development
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P692: Positive histological margins is a risk factor of recurrence after ileocaecal resection in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P693 Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P693: Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of Inflammatory Bowel Disease- An IG-IBD study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P693: Patients with inflammatory bowel disease who are on immunosuppressive therapy perform regular gynecologic screening for uterine cervical cancer?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P693: Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P693: Vedolizumab treatment for pouch inflammation
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P693: Willingness and hesitancy to the telemedicine in patients with inflammatory bowel disease during COVID-19 outbreak. Preliminary results of a survey in an Italian IBD Center
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM